BOCA RATON, Fla., Sept. 07, 2022 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, announces the addition of Mohammad K. Khan, M.D., Ph.D. to its Medical Advisory Board. This appointment increases the size of the Sensus Medical Advisory Board to 10 professionals.
Dr. Khan is a world-renowned physician scientist who currently serves as Professor of Medicine in the Department of Radiation Oncology at the Emory University School of Medicine. As a board-certified radiation oncologist specializing in the treatment of leukemia, lymphoma, melanoma, skin cancer (basal, squamous and Merkel cell), multiple myeloma and pediatric cancers, he treats patients at Winship Cancer Institute of Emory University.
Commenting on his appointment, Dr. Khan said, “I am honored to be named to the Medical Advisory Board for Sensus Healthcare and am glad that we have a portable device to treat skin cancer. This makes it far easier to treat patients closer to home. I look forward to helping further advance SRT for the treatment of non-melanoma skin cancer.”
Joe Sardano, chairman and chief executive officer of Sensus Healthcare, said, “We are delighted that a professional with Dr. Khan’s stature has agreed to serve on our Medical Advisory Board. Although we are well-aware of his impressive work in treating skin cancers, along with research into low-dose radiation in COVID-19 patients, we are optimistic that Dr. Khan will provide important guidance regarding our Superficial Radiation Therapy and other dermatology applications as we continue to develop the marketplace for our products.”
In addition to numerous administrative appointments, Dr. Khan is Research Associate Professor of Engineering in the Department of Nuclear Engineering at the University of Tennessee, Knoxville, Associate Professor in the Department of Nuclear Engineering at the Georgia Institute of Technology, Staff Radiation Oncologist at Children’s Hospital of Atlanta and Chief of Lymphoma, Myeloma, Hematology & Skin Service at Emory University.
Dr. Khan has authored hundreds of scientific abstracts and peer-reviewed articles, and has delivered poster presentations at important conferences such as the annual meetings of the American College of Radiation Oncology (ACRO) and the American Society of Clinical Oncology (ASTRO), along with moderating programs at these and other professional radiation oncology meetings. He is the principal investigator in a Phase 3 study titled “Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19 (RESCUE1-19).”
He holds a B.S. in nuclear engineering and a B.S. in biology from the University of Tennessee, Knoxville, an M.S. in nuclear engineering from the University of Tennessee, Knoxville, an M.D. from the University of Tennessee, Memphis and a Ph.D. in nuclear engineering from the University of Tennessee, Knoxville.
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for both oncological and non-oncological conditions. Sensus offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, including aesthetic lasers and its needleless TransDermal Infusion System™, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world. For more information, visit www.sensushealthcare.com.
Forward-Looking Statements
This press release includes statements that are, or may be deemed, ‘forward-looking statements.’ In some cases, these statements can be identified by the use of forward-looking terminology such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential” or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words.
Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this press release, as a result of the following factors, among others: the continuation and severity of the COVID-19 pandemic, including its impact on sales and marketing; our ability to achieve profitability; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from our international operations; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation, or other aspects of our business; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; and other risks described from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
In addition, even if future events, developments, and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully our “Introductory Note Regarding Forward-Looking Information” and the factors described in the “Risk Factors” section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.
Contact:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com
# # #
